Cosmo Pharmaceuticals N.V Total Liabilities

Latest as of December 2025: €123.46 Million EUR ≈ $144.34 Million USD

Cosmo Pharmaceuticals N.V total liabilities. Based on the latest financial reports, Cosmo Pharmaceuticals N.V (C43) has total liabilities worth €123.46 Million EUR (≈ $144.34 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Cosmo Pharmaceuticals N.V liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Cosmo Pharmaceuticals N.V (2016–2025)

Total liabilities of Cosmo Pharmaceuticals N.V from 2016 to 2025. This chart illustrates how Cosmo Pharmaceuticals N.V's total liabilities have evolved over time, based on quarterly financial data.

Cosmo Pharmaceuticals N.V Competitors by Total Liabilities

The table below lists competitors of Cosmo Pharmaceuticals N.V ranked by their total liabilities.

Company	Country	Total Liabilities
Formosa Taffeta Co Ltd TW:1434	Taiwan	NT$15.73 Billion
Centerspace NYSE:CSR	USA	$1.04 Billion
Black Peony Group Co Ltd SHG:600510	China	CN¥16.28 Billion
BIRLASOFT LIMITED NSE:BSOFT	India	Rs11.98 Billion
Miracle Automation Engineering SHE:002009	China	CN¥3.47 Billion
CBL & Associates Properties Inc NYSE:CBL	USA	$2.39 Billion
Esquire Financial Holdings Inc NASDAQ:ESQ	USA	$2.08 Billion
Southside Bancshares, Inc. NYSE:SBSI	USA	$7.95 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Cosmo Pharmaceuticals N.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Cosmo Pharmaceuticals N.V.

Liquidity & Leverage Metrics

Cosmo Pharmaceuticals N.V Total Liabilities Ratios Explained

Cosmo Pharmaceuticals N.V total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	7.18	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.26	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.20	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cosmo Pharmaceuticals N.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cosmo Pharmaceuticals N.V (2016–2025)

The table below shows the annual total liabilities of Cosmo Pharmaceuticals N.V from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€123.46 Million ≈ $144.34 Million	-12.86%
2024-12-31	€141.68 Million ≈ $165.64 Million	+15.73%
2023-12-31	€122.42 Million ≈ $143.12 Million	-58.61%
2022-12-31	€295.80 Million ≈ $345.83 Million	+1.00%
2021-12-31	€292.88 Million ≈ $342.41 Million	+49.40%
2020-12-31	€196.04 Million ≈ $229.19 Million	+2.41%
2019-12-31	€191.43 Million ≈ $223.80 Million	+5.86%
2018-12-31	€180.83 Million ≈ $211.41 Million	+549.14%
2017-12-31	€27.86 Million ≈ $32.57 Million	-0.21%
2016-12-31	€27.92 Million ≈ $32.64 Million	--

About Cosmo Pharmaceuticals N.V

F:C43 Germany Drug Manufacturers - General

Market Cap

$1.21 Billion

€1.03 Billion EUR

Market Cap Rank

#8641 Global

#1140 in Germany

Share Price

€60.00

Change (1 day)

-2.91%

52-Week Range

€52.90 - €139.00

All Time High

€153.25